PMID- 32425517
OWN - NLM
STAT- MEDLINE
DCOM- 20210625
LR  - 20210625
IS  - 1178-2005 (Electronic)
IS  - 1176-9106 (Print)
IS  - 1176-9106 (Linking)
VI  - 15
DP  - 2020
TI  - Easy to Perform Physical Performance Tests to Identify COPD Patients with Low 
      Physical Activity in Clinical Practice.
PG  - 921-929
LID - 10.2147/COPD.S246571 [doi]
AB  - BACKGROUND: The study investigates which physical performance or muscle 
      function/mass tests significantly correlate with objectively measured physical 
      activity (PA) in patients with chronic obstructive pulmonary disease (COPD) and 
      could potentially serve to identify physically inactive COPD patients in routine 
      clinical practice. METHODS: A cross-sectional, observational study was conducted 
      in outpatients with moderate to very severe COPD. PA was measured during one week 
      with the StepWatch Activity Monitor((R)), an ankle-worn accelerometer, and 
      expressed in steps per day. Physical fitness and peripheral muscle function/mass 
      were evaluated by the 4-meter gait speed (4MGS) test, the 6-minute walk distance 
      (6MWD), the 30-second chair stand test (30sCST), the timed up and go test (TUGT), 
      handgrip strength, arm muscle area, calf circumference, the fat-free mass index 
      (FFMI), and ultrasound measurement of the quadriceps muscle. Spearman's rank 
      correlation analysis and ROC analysis were performed. RESULTS: The study 
      population (N=111, 69% men, mean age 68 years) walked a mean of 8059 steps/day. 
      The daily step count strongly correlated with the 6MWD (rho=0.684, p<0.001) and 
      moderately with the 4MGS (rho=0.464, p<0.001), the TUGT (rho= -0.463, p<0.001), 
      and the 30sCST (rho=0.402, p<0.001). The correlation with the FFMI was weak 
      (rho=0.210, p=0.027), while the other parameters did not significantly correlate 
      with the daily step count. The 6MWD had the best discriminative power to identify 
      patients with very low PA defined as <5000 steps/day (AUC=0.802 [95% CI: 
      0.720-0.884], p<0.001), followed by the TUGT, the 4MGS, and the 30sCST. 
      CONCLUSION: The 6MWD, the 4MGS, the TUGT, and the 30sCST are easy to perform in 
      any clinical setting and may be used by clinicians in the screening of physically 
      inactive COPD patients.
CI  - (c) 2020 Matkovic et al.
FAU - Matkovic, Zinka
AU  - Matkovic Z
AUID- ORCID: 0000-0002-0685-5769
AD  - Department of Internal Medicine, Division of Pulmonary Medicine, Dubrava 
      University Hospital, Zagreb, Croatia.
FAU - Tudoric, Neven
AU  - Tudoric N
AD  - Department of Internal Medicine, Division of Pulmonary Medicine, Dubrava 
      University Hospital, Zagreb, Croatia.
AD  - University of Zagreb, School of Medicine, Zagreb, Croatia.
FAU - Cvetko, Danijel
AU  - Cvetko D
AD  - Department of Diagnostic and Interventional Radiology, Dubrava University 
      Hospital, Zagreb, Croatia.
FAU - Esquinas, Cristina
AU  - Esquinas C
AD  - Pneumology Department, Hospital Universitari Vall d'Hebron/Vall d'Hebron Institut 
      de Recerca (VHIR), CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, 
      Spain.
FAU - Rahelic, Dario
AU  - Rahelic D
AD  - University of Zagreb, School of Medicine, Zagreb, Croatia.
AD  - Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases, 
      Merkur University Hospital, Zagreb, Croatia.
AD  - University of Osijek, School of Medicine, Osijek, Croatia.
FAU - Zarak, Marko
AU  - Zarak M
AD  - Department of Laboratory Diagnostics, Dubrava University Hospital, Zagreb, 
      Croatia.
FAU - Miravitlles, Marc
AU  - Miravitlles M
AUID- ORCID: 0000-0002-9850-9520
AD  - Pneumology Department, Hospital Universitari Vall d'Hebron/Vall d'Hebron Institut 
      de Recerca (VHIR), CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, 
      Spain.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20200424
PL  - New Zealand
TA  - Int J Chron Obstruct Pulmon Dis
JT  - International journal of chronic obstructive pulmonary disease
JID - 101273481
SB  - IM
MH  - Aged
MH  - Cross-Sectional Studies
MH  - Exercise
MH  - Exercise Tolerance
MH  - Female
MH  - *Hand Strength
MH  - Humans
MH  - Male
MH  - Physical Functional Performance
MH  - Postural Balance
MH  - *Pulmonary Disease, Chronic Obstructive/diagnosis
MH  - Time and Motion Studies
PMC - PMC7187939
OTO - NOTNLM
OT  - chronic obstructive pulmonary disease
OT  - exercise capacity
OT  - gait speed
OT  - muscle function
OT  - muscle mass
OT  - physical activity
COIS- Zinka Matkovic has received speaker fees from Abbot Laboratories, AstraZeneca, 
      Berlin-Chemie Menarini and Boehringer Ingelheim, and conference grants from 
      Berlin-Chemie Menarini and Pliva. Neven Tudoric has received speaker fees and 
      conference grants from Chiesi, Berlin-Chemie Menarini, GlaxoSmithKline, 
      AstraZeneca, Boehringer Ingelheim, Cipla, Sandoz, Teva and Novartis, and 
      consulting fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, TEVA, 
      Berlin-Chemie Menarini and Novartis. Dario Rahelic has served as principal 
      investigator or co-investigator in clinical trials of AstraZeneca, Eli Lilly, 
      MSD, Novo Nordisk, Sanofi Aventis, Solvay and Trophos, he has received honoraria 
      for speaking or advisory board engagements and consulting fees from Abbott, 
      Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Lifescan - Johnson & 
      Johnson, Novartis, Novo Nordisk, MSD, Merck Sharp & Dohme, Pfizer, Pliva, Roche, 
      Salvus, Sanofi Aventis and Takeda. Marc Miravitlles has received speaker fees 
      from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, 
      Sandoz, Zambon, CSL Behring, Grifols and Novartis, consulting fees from 
      AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, 
      Kamada, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, 
      TEVA, pH Pharma, Novartis, Sanofi and Grifols, and research grants from 
      GlaxoSmithKline and Grifols. The authors report no other conflicts of interest in 
      this work.
EDAT- 2020/05/20 06:00
MHDA- 2021/06/29 06:00
PMCR- 2020/04/24
CRDT- 2020/05/20 06:00
PHST- 2020/01/19 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/05/20 06:00 [entrez]
PHST- 2020/05/20 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
PHST- 2020/04/24 00:00 [pmc-release]
AID - 246571 [pii]
AID - 10.2147/COPD.S246571 [doi]
PST - epublish
SO  - Int J Chron Obstruct Pulmon Dis. 2020 Apr 24;15:921-929. doi: 
      10.2147/COPD.S246571. eCollection 2020.